Author: Lishan Biotech

Posted Date:

February 8, 2026

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Lishan Biotech

February 8, 2026